S&P 500 Healthcare Sector SEC Filings — March 20, 2026

20-03-2026

Artificial Intelligence Technology Solutions, Inc. (AITX) filed an 8-K on March 20, 2026, announcing a press release stating that its RAD division has booked an order for 5 RIO 360 units destined for the Downtown Civic Center in a major Midwest city. This development underscores demand for AITX's AI-driven security solutions amid otherwise limited financial details in the filing.

• ·Filing includes Exhibit 99.1: Press release dated March 20, 2026

20-03-2026

News Corporation filed an 8-K on March 20, 2026, disclosing information provided to the Australian Securities Exchange (ASX) regarding its ongoing $1B stock repurchase program for Class A and Class B common stock, as required under ASX rules for daily transaction reporting. Exhibits 99.1 and 99.2 contain the specific details provided to the ASX on the respective dates noted therein. No specific repurchase transactions or amounts are detailed in the filing body.

• ·Filing relates to Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits).
• ·Securities: Class A Common Stock (NWSA), Class B Common Stock (NWS), both on Nasdaq Global Select Market.

20-03-2026

Civista Bancshares, Inc. issued a press release on March 19, 2026, announcing plans to release its first quarter 2026 financial results prior to market open on April 22, 2026. The company is a $4.4B financial holding company headquartered in Sandusky, Ohio, with primary subsidiary Civista Bank operating 44 locations across Ohio, Southeastern Indiana, and Northern Kentucky.

• ·Civista Bank founded in 1884
• ·Civista Leasing and Finance Division headquartered in Pittsburgh, Pennsylvania
• ·Common shares traded on NASDAQ under symbol CIVB
• ·Website: www.civb.com

20-03-2026

Cingulate Inc. filed an S-3 registration statement on March 20, 2026, to register up to 3,500,000 shares of common stock (part of a total 6M including prior registration) for resale by Lincoln Park under a July 21, 2025 Purchase Agreement committing up to $25M in common stock purchases over 36 months. The company issued 120,424 commitment shares to Lincoln Park without cash consideration. While this facility offers flexible capital access subject to market conditions and a $0.50 minimum price, it poses substantial dilution risks to existing shareholders, potential stock price declines, and limitations on full utilization due to ownership caps.

• ·Purchase Agreement entered July 21, 2025; 36-month term commencing after conditions met.
• ·Prior S-1 registration filed July 25, 2025 (effective July 29, 2025) for 2,500,000 shares.
• ·Regular Purchases allowed only if last closing sale price >= $0.50.
• ·Agreement terminable by company with one business day's notice without penalty.

20-03-2026

Ermenegildo Zegna N.V. reported FY2025 revenues of €1,917M, down 1.5% YoY from €1,947M in FY2024 (which grew 2.2% from FY2023), with organic growth of 1.1%; while ZEGNA brand rose 1.5%, DTC sales increased 4.2%, and Americas grew 7.9%, Thom Browne declined 14.7%, wholesale branded fell 20.9%, and Greater China dropped 14.6%. Profit improved 20.5% to €109M from €91M, supported by gross margin expansion to 67.5% from 66.6%, though adjusted EBIT fell to €163M from €184M and operating profit margin contracted to 7.3% from 8.6%.

• ·Euro revenues declined to 27.9% of total (from 29.3%), while U.S. Dollar rose to 25.6% (from 23.7%) and Chinese Renminbi fell to 18.4% (from 20.8%).
• ·SG&A expenses increased to 53.9% of revenues from 51.8%, contributing to operating profit decline.
• ·DTC as % of branded products improved to 82.0% from 77.6%, while wholesale share fell to 18.0% from 22.4%.

20-03-2026

Gilead Sciences, Inc. filed definitive additional proxy soliciting materials for its 2026 Annual Meeting on April 30, 2026, at 10:00 a.m. PDT virtually, with voting deadline April 29, 2026. Shareholders are asked to elect nine director nominees, ratify Ernst & Young LLP as auditors for FY 2026, approve NEO compensation advisory, and amend the 2022 Equity Incentive Plan, all recommended FOR by the board; the board recommends AGAINST three stockholder proposals on independent board chair, patent exclusivity impacts, and ESG/DEI compensation risks. No financial or performance metrics are disclosed.

• ·Meeting location: virtually at www.virtualshareholdermeeting.com/GILD2026
• ·Materials request deadline: April 16, 2026

20-03-2026

Precision Optics Corporation, Inc. (POCI) filed an 8-K on March 20, 2026, disclosing matters submitted to a vote of security holders on March 19, 2026, under Item 5.07. The filing includes standard company metadata such as CIK 0000867840, EIN 042795294, and address at 22 East Broadway, Gardner, MA 01440. No specific vote outcomes, financial metrics, or performance data are provided in the content.

• ·SIC: 3845 (Electromedical & Electrotherapeutic Apparatus)
• ·Fiscal year end: June 30
• ·Business phone: 978-630-1800
• ·State of incorporation: MA
• ·SEC file number: 001-10647

20-03-2026

Ameriprise Financial delivered strong 2025 adjusted financial performance, including net revenues of $18.2B (up 6% YoY), adjusted earnings of $3.9B (up 7% YoY), adjusted EPS of $39.34 (up 12% YoY), and AUMAA of $1.7T (up 11% YoY). The company returned $3.4B to shareholders (up 20% YoY) amid a 26.9% adjusted margin (up 40 bps) and 53.3% ROE excluding AOCI (up 60 bps). At the April 29, 2026 virtual annual meeting, shareholders will vote on electing eight director nominees, ratifying PricewaterhouseCoopers LLP as auditors, and approving NEO compensation on an advisory basis.

• ·Annual shareholder meeting: April 29, 2026 at 11:00 a.m. Central time (virtual at www.virtualshareholdermeeting.com/amp2026)
• ·Record date: March 2, 2026
• ·21st consecutive quarterly dividend increase since 2005
• ·7 of 8 director nominees are independent
• ·Directors cannot be nominated after age 75

20-03-2026

Eli Lilly and Company (LLY) filed a DEFA14A Definitive Additional Proxy Materials on March 20, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing indicates no fee was required and is marked as definitive additional materials rather than preliminary or confidential. No specific proposals, financial data, or substantive proxy details are provided in the filing header.

• ·Filing categorized as Definitive Additional Materials (not Preliminary Proxy Statement or Soliciting Material under §240.14a-12)

20-03-2026

First Financial Corporation (THFF) announced that executives Norman D. Lowery (President and CEO), Rodger A. McHargue (SVP and CFO), and Steve Panagouleas (SVP and Chief Credit Officer) will participate in the Raymond James Virtual Roadshow on March 24, 2026. Exhibit 99.1 contains the presentation materials provided to participants, furnished under Regulation FD and not deemed filed.

• ·Filing date: March 20, 2026
• ·Roadshow date: March 24, 2026

20-03-2026

On March 17, 2026, Lifeward Ltd. received a Nasdaq notice of non-compliance with Listing Rule 5605(c)(2)(A) after Hadar Levy's resignation from the Board reduced the Audit Committee to two members, below the required three. The company has a cure period until the earlier of its next annual shareholders' meeting or February 24, 2027 (or August 24, 2026, if the meeting is before then) to regain compliance, with no assurance of success. Shares continue trading on Nasdaq Capital Market under LFWD without immediate delisting impact.

• ·Nasdaq Listing Rule 5605(c)(2)(A) requires audit committee of at least three members.
• ·Company reviewing options to regain compliance per Nasdaq Rule 5605(c)(4).

20-03-2026

Additional proxy materials for the Joint Annual Meeting of Stockholders of AllianceBernstein National Municipal Income Fund (ANMIF) and AllianceBernstein Global High Income Fund (AGHIF), scheduled for March 30, 2026. In FY 2025 (ended 2025), AGHIF's Board and Audit Committee each met 4 times, while ANMIF's Board met 6 times and Audit Committee 4 times. All Directors attended at least 75% of meetings, however Mr. Chaloff attended less than 75% of ANMIF Board meetings.

• ·Fiscal year end: October 31
• ·Filing date: March 20, 2026
• ·Joint Annual Meeting date: March 30, 2026

20-03-2026

Spruce Biosciences reported FY2025 financial results with net loss improved to $39.0M from $53.0M in 2024, driven by R&D expenses decreasing 58% to $19.5M after ceasing tildacerfont development, though G&A expenses rose 16% to $17.0M and collaboration revenue dropped to $0 from $4.9M. Cash and equivalents stood at $48.9M, expected to fund operations into early 2027, supported by an initial $15M tranche from a up to $50M loan facility with Avenue Capital. Positive corporate updates include successful FDA Type B meetings aligning BLA submission for TA-ERT in MPS IIIB for Q4 2026 and appointments of Dale Hooks as CCO and others to leadership.

• ·Stock-based compensation expenses decreased to $2.6M in FY2025 from $5.3M in FY2024.
• ·Total assets increased to $53.0M as of Dec 31, 2025 from $45.2M as of Dec 31, 2024.
• ·Accumulated deficit grew to $(289.2M) as of Dec 31, 2025 from $(250.3M) as of Dec 31, 2024.
• ·Net loss per share improved to $(50.83) in FY2025 from $(96.40) in FY2024.
• ·PRV program reauthorized through Sep 30, 2029; TA-ERT eligible if approved.

20-03-2026

Artelo Biosciences, Inc. (ARTL) filed an S-1 registration statement on March 20, 2026, for a public offering of common stock and pre-funded warrants through placement agent Craft Capital Management LLC, with 8.0% fees and warrants equal to 8.0% of securities sold. Interim Phase 2a CAReS trial results for ART27.13 showed compelling efficacy with mean body weight gain of 6.38% (vs -5.42% placebo loss) and lean body mass increase of +4.23% (vs -3.15% placebo) in 18 evaluable cancer anorexia patients, with a favorable safety profile among 32 enrolled participants. ART26.12 Phase 1 SAD study in 49 healthy subjects reported no drug-related adverse events and dose-dependent pharmacokinetics.

• ·ART27.13 dose escalation approved up to 1,300 micrograms; max weight gain 18.5% (ART27.13) vs 0.4% (placebo); max weight loss -3.0% (ART27.13) vs -17.4% (placebo).
• ·ART12.11 composition of matter patent enforceable until December 10, 2038.
• ·ART26.12 IND cleared by FDA in July 2024; Phase 1 results announced June 2025.
• ·CAReS trial: first patient dosed April 2021; Phase 1b completed Q1 2023; Phase 2a initiated April 2023; interim announced September 3, 2025.

20-03-2026

EWSB Bancorp, Inc. filed amended and restated bylaws governing stockholder meetings, including procedures for annual and special meetings called by the President, CEO, Chairperson, Board, or stockholders holding a majority of votes. The bylaws specify notice requirements (10-90 days), quorum (majority of shares), adjournment/postponement rules (up to 120 days), and strict advance notice for business proposals and director nominations (90-100 days prior to annual meeting anniversary, with adjustments for changes in meeting dates). Special provisions apply to the first annual meeting after becoming sole stockholder of East Wisconsin Savings Bank.

• ·Special meetings called only by President, CEO, Chairperson, Board (majority of Whole Board), or stockholders entitled to majority of votes, with Board fixing record date, meeting details.
• ·Stockholder notice for proposals/nominations: delivered 90-100 days before prior year's annual meeting anniversary; if advanced >30 days, between public disclosure and 10th day after.
• ·Notice by electronic transmission per Maryland General Corporation Law; waivers allowed.

20-03-2026

Gladstone Commercial Corporation filed definitive additional proxy materials (DEFA14A) for its 2026 Annual Meeting on May 7, 2026, recommending shareholders vote for the election of director nominees Michela English and Anthony Parker, and to ratify PricewaterhouseCoopers LLP as the independent auditor for the fiscal year ending December 31, 2026. Voting must be completed by May 6, 2026, 11:59 PM ET, with proxy materials available online or requestable by April 23, 2026. No financial metrics or performance data are disclosed in this filing.

• ·Meeting held virtually at www.virtualshareholdermeeting.com/GOOD2026
• ·Address: 1521 Westbranch Drive, Suite 100, McLean, VA 22102

20-03-2026

Louisiana-Pacific Corporation (LPX) filed definitive additional proxy materials (DEFA14A) for its 2026 Annual Meeting of Stockholders, scheduled virtually on May 1, 2026 at 7:30 a.m. CT. Key proposals include the election of three Class II directors (Jose A. Bayardo, Stephen E. Macadam, Jean-Michel Ribiéras), ratification of Deloitte & Touche LLP as independent auditors for 2026, and an advisory vote to approve named executive officer compensation, with the Board recommending 'FOR' all items. Shareholders must vote by April 30, 2026, 11:59 PM ET, and can request paper copies by April 17, 2026.

• ·Meeting URL: www.virtualshareholdermeeting.com/LPX2026
• ·Voting platform: www.ProxyVote.com (Control # V84154-P42817)
• ·Company address: 1610 West End Avenue, Suite 200, Nashville, Tennessee 37203
• ·Filing date: March 20, 2026

20-03-2026

Heritage Financial Corporation reported strong 2025 profitability with net income up 56.1% YoY to $67.5 million and diluted EPS rising 58.1% to $1.96, alongside deposit growth of 4.1% to $5.92 billion and dividends increasing 4.3% to $0.96 per share. However, total assets declined 2.0% to $6.97 billion, net loans fell slightly 0.4% to $4.73 billion, and overhead ratio worsened 6.3% to 2.36%, impacted by $10.7 million in pre-tax losses from securities sales and $1.0 million in merger costs with Olympic Bancorp (effective January 31, 2026). The proxy statement solicits votes for electing 11 directors, advisory approval of executive compensation, and ratification of Crowe LLP as auditors at the virtual annual meeting on May 7, 2026.

• ·Record date for shareholders: March 9, 2026
• ·Board composition: average age 61 years, 55% diversity (4 gender, 2 ethnic), average tenure 11 years, 91% independent (10 of 11 directors)
• ·Virtual meeting access: www.meetnow.global/MYZUC44

20-03-2026

Exact Sciences Corporation announced that, as of March 19, 2026, it and Abbott Laboratories have received all required regulatory approvals for their previously announced merger, following stockholder approval on February 20, 2026. The merger, under the Agreement and Plan of Merger dated November 19, 2025, is anticipated to close on March 23, 2026, subject to remaining conditions. The filing highlights forward-looking risks including potential delays, termination fees, and adverse impacts on business operations.

• ·Merger agreement originally entered on November 19, 2025
• ·Exact Sciences to survive as a wholly owned subsidiary of Abbott post-merger
• ·Risks include potential termination fee payment by Exact and diversion of management attention

20-03-2026

CNA Financial Corporation's definitive proxy statement for its 2026 Annual Meeting on April 29, 2026, solicits votes for electing 10 Board nominees (following Dino E. Robusto's resignation on December 31, 2025, fixing Board size at 10), an advisory vote approving named executive officer compensation, amending the Incentive Compensation Plan to authorize an additional 5,000,000 shares, and ratifying Deloitte & Touche LLP as 2026 independent auditors. The record date is March 6, 2026, with 269,918,371 shares of Common Stock outstanding. The Board recommends FOR all proposals, with no reported controversies or declines noted.

• ·Annual Meeting location: 151 N. Franklin Street, 7th Floor Navy Pier 3 Room, Chicago, Illinois 60606 at 7:30 a.m. Central time.
• ·Voting methods: Internet (www.proxyvote.com), phone (1-800-690-6903), or mail to Broadridge.
• ·Proxy materials and 2025 Annual Report available at www.cna.com.

20-03-2026

ENB Financial Corp reported strong YoY growth for 2025, with net interest income rising 21.1% to $68.7M and net income surging 40.8% to $21.6M, driven by higher loan volumes (+5.3% average) and interest rates. However, total deposits declined 0.9% to $1.87B at year-end, securities available for sale fell to $579M from $616M, and operating expenses increased 7.0% to $59.1M amid merger-related costs. Net yield on interest earning assets improved to 3.19% from 2.87%, while other income remained flat at ~$18M.

• ·Basic and diluted EPS increased to $3.80 from $2.71 (+40.2%).
• ·Dividends per share $0.72 vs $0.69.
• ·Allowance for credit losses $16.9M vs $16.1M.
• ·Noninterest-bearing deposits grew to $649M from $632M (+2.8%).
• ·Average total assets $2.21B vs $2.04B (+8.2%).
• ·Deferred loan fees recognized: ($0.245M) in 2025 vs ($0.115M) in 2024.

20-03-2026

PAR Pacific Holdings, Inc. (PARR) filed a DEFA14A Definitive Additional Proxy Materials on March 20, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. This filing serves as additional solicitation material with no fee required. No financial metrics, performance data, or substantive proxy details are disclosed in the provided header.

• ·Filed by the Registrant
• ·No fee required for filing